Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01961115 · ClinicalTrials.gov registry record · Phase 2
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01961115 is a Phase 2 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 11 participants.
The verdict
NCT01961115, a Phase 2 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma.
Interventions
- DRUG Epacadostat
- BIOLOGICAL MELITAC 12.1 Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2013-09-13 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01961115
The ClinicalTrials.gov registry entry for NCT01961115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epacadostat is the first listed.
NCT01961115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01961115 about?
NCT01961115 is a clinical study titled "Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma". This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an ...
What is the current status of trial NCT01961115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2013-09-13. Estimated completion is 2017-05-18.
What interventions are being tested in trial NCT01961115?
The interventions under investigation include: Epacadostat (DRUG), MELITAC 12.1 Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01961115?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.